"Dr. van der Horst and colleague Christopher Hurt, from UNC’s Center for Infectious Diseases, are each leading the first studies of medications for IV treatment of influenza"
http://www.wchl1360.com/details3.html?id=12650
Dr. van der Horst, professor of medicine and infectious diseases at UNC, says Lillian Chason, the UNC student in critical condition with swine flu, has been receiving a new form of treatment.
Relenza, or properly known as Zanamivir, is usually inhaled for treating and preventing influenza. Dr. van der Horst and colleague Christopher Hurt, from UNC’s Center for Infectious Diseases, are each leading the first studies of medications for IV treatment of influenza.
Dr. van der Horst says Chason’s case is a good example for why IV treatment for the flu, whether seasonal or H1N1, is over due. The UNC freshman is on a ventilator and cannot be orally administered Tamiflu and can’t inhale the aerosolized Relenza.
BTA Price at posting:
$2.97 Sentiment: Hold Disclosure: Held
